Immediate Impact
57 standout
Citing Papers
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials
2024 Standout
Targeting cytokine and chemokine signaling pathways for cancer therapy
2024 Standout
Works of Wei Jing Loo being referenced
Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study
2023
Dermatology Life Quality Index: influence of an illustrated version
2003
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Wei Jing Loo | 154 | 60 | 89 | 67 | 25 | 293 | |
| John W. Petrozzi | 142 | 43 | 81 | 52 | 31 | 309 | |
| Caitlin M. Brumfiel | 138 | 33 | 56 | 62 | 25 | 222 | |
| Yavuz Harmanyeri | 75 | 80 | 88 | 49 | 17 | 245 | |
| Kierland Rr | 79 | 109 | 88 | 123 | 19 | 334 | |
| Dilek Bıyık Özkaya | 142 | 35 | 63 | 68 | 29 | 252 | |
| Piotr Sobolewski | 123 | 41 | 106 | 119 | 28 | 276 | |
| Filiz Canpolat | 94 | 62 | 99 | 39 | 25 | 272 | |
| P. Modiano | 98 | 86 | 29 | 37 | 29 | 281 | |
| Maria Laura Flori | 216 | 29 | 62 | 45 | 22 | 329 | |
| Paul I. Dantzig | 110 | 85 | 42 | 102 | 17 | 295 |
All Works
Loading papers...